Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Kinross Gold Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.91 (market cap $39.89B), while Kinross Gold Corporation trades at $23.61 (market cap $28.72B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Kinross Gold Corporation pays a 0.6% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | KGC | |
|---|---|---|
Market Cap | $39.89B | $28.72B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $38.06 |
52-Week Low | $278.09 | $15.33 |
Enterprise Value | $38.15B | $27.28B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
KGC trades at $24.14, down 0.25% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals, with revenue growing from $3.5B in 2022 to $7.05B in 2025 and net income surging to $2.39B. Valuation ratios are attractive, including a P/E of 10.27 and EV/EBITDA of 5.3. Recent earnings have consistently beaten expectations, and a dividend of $0.04 per share was declared for H1-26.
The outlook is positive due to robust cash flow growth, a healthy balance sheet, and analyst consensus favoring a buy rating with a $36.25 price target. Key risks include potential margin pressure from rising costs and broader market volatility affecting gold prices. The stock presents a value opportunity if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
